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Leprosy is a notifiable chronic infectious disease caused by 
Mycobacterium leprae that primarily affects the skin and peripheral 
nerves.[1,2] Other organs such as the eyes, mucosae, bones and 
testes may be affected.[3] Leprosy often results in severe, lifelong 
disabilities and deformities.[2] Through awareness and early medical 
intervention, a reduction in disabilities is possible. Neurological 
damage is irreversible and often requires lifelong care.[4] The World 
Health Organization (WHO) declared leprosy eliminated as a public 
health problem in 2000 based on the achievement of a global 
prevalence of <1 case of leprosy per 10 000 people.[3,4]
There are regions and countries where leprosy is still endemic, 
and these carry the bulk of global cases.[2,5] In 2015, the highest 
incidence of the disease was found in India, Brazil and Indonesia, 
together accounting for 81%, while Africa contributed ~9% to the 
global incidence.[2,6] In 2016, the WHO committed to strategies of 
reducing the disease burden to achieve a world free of leprosy.[5] These 
focused on strengthening government ownership, co-ordination and 
partnership; strategies to further reduce leprosy and its complica tions; 
and tackling discrimination and stigma associated with leprosy.[5]
Middle age is the most common age of presentation, with males 
most often affected.[7-9] The latter has been attributed to male 
migration patterns.[10] Data from multiple countries suggest that 
infections in females are detected late.[11] The proportion of infected 
children aged <15 years varies, ranging from 1.9% to 18%.[7,10,12,13]
Risk factors for contracting leprosy include low socioeconomic 
status, poor education, contact with leprosy, and genetic factors. [3] 
These may influence endemicity, but they do not fully explain the 
differences in endemicity that exist between African and Asian 
regions.[6] Close prolonged contact with an infected patient increases 
the risk by five to eight times.[8,14] A study found that 62% of new 
cases had contact history in a low-endemic area compared with 
25% in a high-endemic area.[13] In 2016, foreign-born patients 
contributed 100% of new cases in Qatar and the United Arab 
Emirates, highlighting the disparity in distribution of leprosy.[2]
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Background. The World Health Organization announced a strategy to eliminate childhood leprosy infections, visible deformities 
and discriminatory legislation against leprosy patients by 2020. However, challenges in achieving a leprosy-free world and preventing 
neurological sequelae still exist. HIV infection is a challenge in South Africa (SA). HIV-leprosy co-infection may result in an increase in the 
frequency of leprosy reactions without affecting the spectrum of leprosy. From 1921 to 1997, the prevalence of leprosy remained <1 patient 
per 10 000 population. Current SA literature has very scanty information regarding leprosy infections.
Objectives. To describe the trend of new leprosy patients at Chris Hani Baragwanath Academic Hospital, Johannesburg, SA, from 1999 to 
2015, including demographics, clinical spectrum and treatment outcomes.
Methods. A retrospective review of patients’ clinical records was undertaken. Data on demographics, clinical spectrum including the 
leprosy classification, reactions, neurological involvement, association with HIV infection and treatment outcomes were extracted. Data 
analysis was performed using descriptive and inferential statistics and a time series analysis.
Results. An upward trend from 1999 to 2001 was followed by a decline in the number of new patients. Eighty patients were registered 
over a period of 17 years, with a male-to-female ratio of 3:1. Thirty-six patients were immigrants, and 5 were children aged <15 years. 
Multibacillary leprosy was the most common type (n=71 patients). Thirty-six patients had the lepromatous leprosy subtype, 22 were 
borderline lepromatous, 13 were borderline tuberculoid, 6 were borderline borderline, and 3 had tuberculoid leprosy. Thirty-one patients 
presented with reactions, type 1 in 9 patients and type 2 in 21 patients, with both types in 1 patient. Grade 2 neurological deformities 
were diagnosed in 37 patients, of whom 2 were children. Eight patients were found to have HIV-leprosy co-infection. Of 52 patients who 
completed treatment, 26 were cured and 26 were lost to follow-up. Twenty-one patients defaulted from treatment, while 3 patients relapsed.
Conclusions. This study highlights the current status of leprosy in a low-endemic centre with declining numbers of new patients. 
Multibacillary forms with grade 2 disabilities (G2Ds) are common. The constant emergence of leprosy in our population highlights 
shortfalls in our control campaigns. Furthermore, a high rate of G2Ds necessitates scrutiny of education directed at early patient detection 
and follow-up strategies.
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Leprosy has a myriad of clinical presentations that depend on 
cell-mediated immune response to the bacilli. A simple WHO 
classification is used for the current treatment model (Table 1).[3,15]
The Ridley-Jopling classification (RJC) uses the spectrum of 
cell-mediated responses to the bacilli, divided into five categories 
that range from mild tuberculoid leprosy (TT) to the most severe 
lepromatous leprosy (LL), as summarised in Table 2. In between these 
extremes lie immunologically unstable forms, borderline tuberculoid 
(BT), borderline borderline (BB) and borderline lepromatous (BL), 
which can evolve to either TT or LL poles by downgrading or 
upgrading.[16-18] A form where an immune response has not yet 
developed is called indeterminate leprosy.[19]
Leprosy reactions are inflammatory reactions due to T-lymphocyte 
activation or circulating immune complexes resulting in leuko-
cytoclastic vasculitis.[20] Type 1 reactions, which are delayed-type 
hypersensitivity, include upgrading (also known as reversal), 
representing a shift towards the TT pole, and downgrading reactions, 
which represent a shift towards the LL pole.[3,20-22] Upgrading reactions 
are often seen during initiation of treatment.[6] Type 1 reactions are 
characterised by erythema, induration or ulceration of existing skin 
lesions as well as nerve pain or tenderness, which may be followed 
by loss of function. Type 1 reactions are frequent in borderline forms 
(BT, BB and BL), which are immunologically unstable.[3,21,22] Type 2 
reactions, also known as erythema nodosum leprosum (ENL), are 
caused by an acute immune complex vasculitis affecting the skin and 
other organs, commonly seen in lepromatous subtypes (LL and BL) 
with high bacillary loads.[3,6,21] These present as new erythematous 
painful nodules, pustules or ulcers. Other features include fever, 
lymphadenopathy, arthritis, neuritis, glomerulonephritis, irido-
cyclitis, orchitis and dactylitis.[6,23]
Lucio’s phenomenon is a rare leprosy reaction caused by 
direct endothelial cell damage, characterised by acute painful 
necrotic ulcers associated with fever, anaemia, lymphadenopathy 
and hepatosplenomegaly.[3] In a study where borderline forms 
predominated, Chhabra et al.[9] reported that more patients presented 
with type 1 reactions (n=258/849) than with type 2 (n=60/849). In 
a review, Kahawita et al.[22] demonstrated a varying type 1 reaction 
prevalence rate ranging from 19% to 29%. Leprosy reactions are 
more frequent in patients co-infected with HIV, and the rapid-phase 
immune reconstitution seen with the initiation of HIV treatment 
allows for manifestations of pre-existing leprosy.[24,25] Systemic 
steroids are used to treat all types of leprosy reactions, with high 
doses in Lucio’s phenomenon.[22,26] In addition, analgesia, clofazimine 
and thalidomide are used in treatment of type 2 reactions.[22]
Inclusion of leprosy in the differential diagnosis is a major 
challenge in non-endemic settings.[27] A high index of suspicion and 
interpretation of clinical signs as shown in Table 2 are the mainstay 
of the diagnosis. Demonstration of M. leprae by slit-skin smears, 
histopathology or polymerase chain reaction is useful to confirm the 
diagnosis. Limited availability of laboratory facilities in some areas 
makes clinical diagnosis important.[19,26]
Multidrug treatment (MDT) comprising a combination of 
rifampicin, dapsone and clofazimine for 12 months in multibacillary 
(MB) leprosy and for 6 months in paucibacillary (PB) leprosy is 
recommended by the WHO.[3,5,28] Adjusted doses of MDT are used 
in children.[26] MDT prevents resistance, induces a rapid decline 
in infectivity, and decreases the rate of recurrence.[26] The Leprosy 
Mission distributes the leprosy MDT in South Africa (SA) through 
its partnership with the WHO. Cure rates ranging between 64% and 
100% have been reported.[7,28] Reported relapse rates vary between zero 
and 20% following MDT.[29-32] Relapses tend to occur between 3.5 and 
6 years after MDT completion, and are associated with higher bacillary 
loads.[29,31] Resistance to rifampicin and dapsone as well as to secondary 
therapies such as ofloxacin has been reported to be as high as 8%.[26]
Table 1. A summary of the World Health Organization classification of leprosy and treatment[3,15]
Paucibacillary Multibacillary
Number of lesions 1 - 5 >5
Symmetry Asymmetrical Symmetrical 
Lesional anaesthesia Always Sometimes 
Bacterial index <2 at all sites ≥2 at any site
Treatment 6 months completed within 9 months 12 months completed within 18 months
Table 2. A summary of clinical features of leprosy based on the Ridley-Jopling classification[15,16,19,20]
Tuberculoid Borderline tuberculoid Borderline borderline Borderline lepromatous Lepromatous
Number of lesions 1 - 3 asymmetrical ≥4 asymmetrical Few to many 
(countable)




Skin lesions Well defined; large 
hypopigmented 
or erythematous; 
patch or plaques; 
hairless, dry
Well defined; smaller 
macules or plaques; 
satellite lesions
Irregular shapes; 








patches, plaques or 
nodules; ill-defined 
borders
Nerves 1 or 2 enlarged Few; asymmetrically 
enlarged
Numerous; may be 
symmetrically enlarged







None Reduced May or may not be 
reduced
May or may not be 
reduced
Normal 
Bacilli on smear Few May or may not be seen May or may not be seen Numerous Numerous
Immunity High Unstable immune responses able to migrate either way Low 
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Understanding of the current leprosy situation in our setting relies 
on documented information in the literature. This information 
is currently scarce in SA. Furthermore, despite global efforts to 
eliminate leprosy, it continues to spread in SA, causing recognisable 
morbidity. Studying leprosy patterns at Chris Hani Baragwanath 
Academic Hospital (CHBAH), which is the largest hospital in SA, will 
therefore assist efforts to understand its patterns in the country.[33]
Objectives
To describe the current leprosy trends, demographics and clinical 
spectrum, and to determine the treatment outcomes of patients 
treated for the disease at CHBAH from 1999 to 2015.
Methods
Study sample
We retrospectively reviewed clinical records of 80 adult and paedia-
tric patients diagnosed with and treated for leprosy at CHBAH from 
1 January 1999 to 31 December 2015. The hospital is a designated 
referral treatment centre for leprosy patients in Johannesburg, 
the largest city in SA. The population of Johannesburg is diverse, 
including immigrants from various parts of Africa and other parts of 
the world. For the purposes of data analysis, patients aged <15 years 
were classified as children.
Data collection
The data collection instrument was a data sheet. The diagnosis of 
leprosy was based on clinical examination, histopathological findings 
or slit-skin smear results. The demographic data obtained included 
age at diagnosis, gender, region of origin, and history of leprosy 
contact. Using the United Nations Sub-Saharan African divisions and 
the world map, regions of origin were divided into northern, central, 
eastern, western and southern Africa, and Asia or other, based on 
where the patients were born. The southern Africa region was further 
divided into member countries, and SA was divided into provinces. 
The trend was formulated using the total number of new leprosy 
patients over the years. Patients who relapsed and were admitted to 
our centre for retreatment were excluded in formulation of the trend 
of new cases.
The clinical examinations were carried out by a doctor. The skin-
slit smears were done by a technician and stained by modified Ziehl-
Neelsen methods. The histopathological findings were obtained 
from skin biopsy reports analysed and reported by the SA National 
Health Laboratory Service. HIV-positive status was confirmed on 
antibody or antigen (rapid or enzyme-linked immunosorbent assay) 
tests. Initial CD4 counts in cells/µL at the time of presentation were 
used. The information on the clinical spectrum of leprosy included 
the leprosy classification, reactions, neurological involvement, and 
association with HIV infection.
Records were classified into WHO categories, PB if the number of 
skin lesions was ≤5 and MB if there were >5.[15] In addition, a record 
was classified into one of the RJC variants, i.e. TT, BT, BB, BL and LL, 
using a combination of clinical assessment, slit-skin smear results and 
histopathological findings.[15]
Information on the leprosy reactions the patient presented with 
during the course of the follow-up period was captured. A type 
1 reaction was diagnosed when rapid swelling and erythema of 
existing skin lesions was noted.[21] Type 1 reactions were classified as 
downgrading if occurring in untreated patients as borderline forms 
shifts towards the LL pole, and upgrading if occurring with antibiotic 
treatment.[20] A type 2 reaction was diagnosed if a patient presented 
with a new painful erythematous nodule, with histopathological 
features of neutrophilic leukocytoclastic vasculitis A, or with arthritis, 
neuritis, glomerulonephritis, iridocyclitis, orchitis and dactylitis.[23]
Information on neurological involvement obtained from the records 
was represented by disability grade.[1] For peripheral nerve involvement, 
grade 0 represented no impairment, grade 1 anaesthesia of hands or 
feet with no visible deformity, and grade 2 presence of both anaesthesia 
and visible deformities such as trophic ulcers, claw deformities and 
bone resorption in the extremities.[1] For the eyes, grade 0 represented 
no vision loss related to leprosy, grade 1 some visual impairment 
(vision 6/60 or better), and grade 2 severe loss of vision.[1]
The considered treatment outcome variables were treatment 
completed, and patient cured, transferred, relapsed, died or defaulted. 
Treatment was deemed completed if a PB patient completed the WHO-
recommended 6 months of MDT within a 9-month period, and in MB 
patients if 1 year of MDT was completed within 18 months.[5,28,34]
Cure was defined as bacillary index (BI) negativity in MB types and 
complete disappearance of the skin lesion(s) in PB types.[28] Relapse 
was defined as appearance of a new lesion or an increase in size of 
the lesion, erythema or swelling where it had subsided, confirmed 
histologically by granuloma reappearance in PB types, increased 
macrophage infiltration with solid bacilli in MB types, or 2+ increase 
in BI following successful treatment.[31] Cure and relapse were assessed 
every 6 months up to 18 months for PB and up to 24 months for MB, 
which constituted a period of 1 year’s follow-up post treatment.
Patients were considered as having defaulted if they did not take 
their medication for >3 months (PB infection) or >6 months (MB 
infection).[34] Patients who were sent to other centres for treatment 
completion were considered transferred. Those who lost their lives 
during the study period were recorded as having died.
Statistical analysis
Data analysis and interpretation was conducted using both descrip-
tive and inferential statistics. Descriptive statistics were used to 
describe the distribution of the data using measures such as means, 
standard deviations (SDs), minimums and maximums for numerical 
variables such as age, while frequencies and graphs were used to 
report categorical variables. The number of leprosy patients was 
reported as frequencies or percentages. A line graph was used to show 
the trend in numbers of leprosy patients over time.
For categorical variables such as age category, gender, country 
of origin, history of contact, classification, leprosy reactions, 
neurological involvement, association with HIV and treatment 
outcome, frequencies and percentages were reported. Graphical 
demonstration to visually display the results was done using pie charts 
or bar charts. Inferential statistics were used to make judgements 
based on the sample data collected. The χ2 test was used to ascertain 
associations between the categorical variables if its assumptions were 
satisfied; otherwise Fisher’s exact test was used. The χ2 test was used 
to test for association between the RJC and leprosy reaction as well as 
between HIV status and leprosy reaction.
Ethical considerations
Anonymised data were used, with patients’ identity protected, and all 
collected data were secured. Permission for analysis and publica tion 
was obtained from the Human Research Ethics Committee of the 
University of the Witwatersrand (ref. no. M180951).
Results
Demographic characteristics
A total of 80 leprosy patient records were reviewed in the study. 
The majority (n=70) were new patients, while 10 (12.5%) were 
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relapses after MDT. The sociodemographic features of all patients 
are summarised in Table 3. There was a preponderance of males 
(76.2%), with a male-to-female ratio of 3:1. Only 5 patients (6.2%) 
were children aged <15 years. The minimum and maximum ages of 
the participants were 4 and 73 years, respectively, with the mean (SD) 
age 36 (15.27) years.
The majority of the patients (73.8%; n=59) were from the southern 
African region. A total of 56 patients (70.0%) did not have any history 
of contact with a leprosy patient (Table 3).
Further division of the southern African region showed that 
SA-born individuals comprised the highest number (n=44) of 
leprosy patients compared with migrant groups from this region, i.e. 
Mozambique (n=10), Swaziland (n=2), and Lesotho, Namibia and 
Zambia (n=1 each).
Of the 44 SA-born patients, most were originally from Gauteng 
and KwaZulu-Natal (KZN) provinces, with 17 patients each, 4 were 
from Mpumalanga, 3 were from Limpopo, 2 were from Free State and 
1 was from North West.
Trend
The number of new leprosy patients showed a decline after 2001 
(Fig. 1). Before this period, from 1999 to 2001, an upward trend was 
recorded. After 2004 the number of new patients stabilised, with very 
little change until 2015.
Clinical spectrum
Classification
As shown in Table 4, 71 patients (88.8%) had MB leprosy and 9 
(11.2%) PB. According to the RJC, the majority (45.0%; n=36) were 
classified as having LL (Fig. 2).
Leprosy reactions
Most patients (n=49) had no leprosy reaction, and the breakdown 
of leprosy reactions is shown in Table 4. All type 1 reactions were 
upgrading reactions. Of the 21patients with ENL, 17 had the LL 
variant. The upgrading reaction was found in the LL (n=1), BL (n=4), 
BB (n=1) and BT (n=3) groups. One patient with BL had both ENL 
and upgrading reactions, as shown in Table 5.
Neurological involvement
From the available data, 37 patients (46.2%) had grade 2 neurological 
disability, 2 of whom were children, as shown in Table 4. Patients with 
the LL variant formed the majority (n=26) of those with neurological 
disability, 17 of whom had grade 2 disabilities (G2Ds), as shown in 
Table 5.
Association with HIV
Of the patients, 23 (28.7%) tested negative for HIV and 8 (10.0%) 
tested positive, while in 49 (61.3%) HIV testing was not done. Of the 
8 patients with a positive HIV result, 6 had a CD4 count >200 cells/
µL and only 1 had a CD4 count <200 cells/µL. CD4 count testing was 
not done on the rest of the patients. Of the HIV-positive patients, 2 
had ENL, compared with 8 who were HIV-negative. Fisher’s exact 
test indicated that there was no association between HIV status and 
leprosy reaction (p=0.584).
Treatment outcomes
Of the patients, 52 had completed treatment and 26 (50.0%) were 
cured. Cure was not documented for the other half. A total of 21 
(26.2%) defaulted, 3 (3.8%) experienced relapse and 4 (5.0%) were 
transferred (Table 6).
Discussion
This study reports on leprosy patterns at CHBAH. A male predomin-
ance was noted, which is consistent with global evidence[8-10,35] and 
Table 3. Baseline demographics (N=80)
Description n (%)
Entry status
New patients 70 (87.5)






15 - 30 29 (36.2)
31 - 45 26 (32.5)
46 - 60 14 (17.5)
61 - 75 6 (7.5)
Region of origin
Asia 6 (7.5)
Central Africa 5 (6.2)
Eastern Africa 8 (10.0)
Southern Africa 59 (73.8)




MDT = multidrug treatment.
Table 4. Clinical spectrum (N=80)
Clinical spectrum Description n (%)
WHO classification MB 71 (88.8)
PB 9 (11.2)
Leprosy reaction Type 1 9 (11.2)
Type 2/ENL 21 (26.2)
None 49 (61.2)
Both type 1 and type 2 1 (1.2)
Neurological disability Grade 0 19 (23.8)
Grade 1 24 (30.0)
Grade 2 37 (46.2)
WHO = World Health Organization; MB = multibacillary; PB = paucibacillary; ENL = erythema nodosum leprosum.
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may be due to socioeconomic differences 
in favour of men, making healthcare access 
easier for them. The mean age of presenta-
tion was in the middle-age group, which 
is consistent with the findings of other 
similar studies. [7-9] This group represents the 
workforce, who are often breadwinners in 
families and therefore of great concern. Very 
few patients were children (<15 years old), in 
line with the findings of other studies.[10,12,35]
Around half of the patients were SA-born, 
with leprosy most common in patients 
from Gauteng and KZN. This finding is of 
concern, as it may indicate clusters of active 
infection transmission in these locations. 
The high proportion of patients originating 
from Gauteng may be a result of easier access 
to CHBAH. The presence of a similarly high 
proportion from KZN, which surpasses that 
of neighbouring provinces, is concerning 
as it may indicate the presence of higher 
numbers of patients with active infection 
in the province. The immigrant population 
comprised about half of the total number of 
our patients.
The study found that more than two-
thirds of patients had no known history of 
contact with an index patient.[36] Richardus 
et al.[13] found a lower proportion (one-third) 
of new leprosy patients with no contact 
history in low-endemic Thailand compared 
with high-endemic Bangladesh. Our study 
was done in SA, which is a low-endemic 
area; however, our proportion of patients 
who had no history of contact was higher.
An increasing trend from 1999 to 2001 
was followed by a decline from 2001, which 
stabilised in 2004 with very little change 
in numbers thereafter. The reason for the 
increasing number of leprosy patients 
during the earlier period is unclear, but 
it may represent a period of increased 
influx of immigrants from leprosy-endemic 
neighbouring countries. The declining 
trend noted from 2001 is similar to patterns 
described worldwide.[37,38]
We identified a predominance of MB 
patients in our study (88.8%), with LL 
forming the majority of cases in this group. 
The WHO reported that in the Democratic 
Republic of the Congo and Ethiopia, 60 - 80% 
of new patients detected in 2016 had MB 
forms.[2] A similar pattern of predominance 
of MB forms has been recorded in other 
similar studies.[7,8,12] The predominance of 
MB forms in our population may be due to 
poor immunity against leprosy.
In the present study, 26.2% of patients had 
type 2 reactions, while 11.2% had a type 1 
reaction at some point during their follow-up 
period. Previous studies have found varying 
prevalence rates of type 1 reactions, ranging 
from 19% to 30%.[9,22] The lepromatous 
group (LL and BL) predominated in our 
study, so it is not surprising that type 2 
reactions were common.
Nearly half (46.2%) of our patients had 
G2Ds, 5.4% of whom were children. Varying 
proportions of patients with G2Ds have 
been reported. In a global leprosy update in 
2016, the WHO reported that 14.5% of new 
leprosy patients had G2Ds in the African 
region compared with 4.6% in the south-


















Fig. 1. Trend in number of new leprosy patients, 1999 - 2015 (N=80).
Table 5. Leprosy reactions and neurological disability (N=80)
RJC
                                Leprosy reactions, n Neurological disability, n
ENL Upgrading ENL and upgrading None Grade 0 Grade 1 Grade 2
LL 17 1 0 18 10 9 17
BL 4 4 1 13 5 8 9
BB 0 1 0 5 1 1 4
BT 0 3 0 10 1 6 6
TT 0 0 0 3 2 0 1
RJC = Ridley-Jopling classification; LL = lepromatous leprosy; BL = borderline lepromatous; BB = borderline borderline; BT = borderline tuberculoid; TT = tuberculoid leprosy; ENL = erythema 
nodosum leprosum.
Table 6. Treatment outcomes (N=80)
RJC
Treatment outcome, n/n (%)
                             Completed
Defaulted Relapsed TransferredCure not documented Cured 
LL 15 10 11 0 0
BL 3 7 8 3 1
BB 3 1 1 0 1
BT 3 7 1 0 2
TT 2 1 0 0 0
Total 26 (32.5) 26 (32.5) 21 (26.2) 3 (3.8) 4 (5.0)
RJC = Ridley-Jopling classification; LL = lepromatous leprosy; BL = borderline lepromatous; BB = borderline borderline; BT = borderline tuberculoid; TT = tuberculoid leprosy.
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patients with G2Ds have been reported in similar studies.[7,10] Delay 
in diagnosis and default in treatment are among the high risk factors 
for G2Ds.[7,39] The high percentage of G2Ds in the present study 
may indicate late presentation or delayed diagnosis in our region. 
Furthermore, the percentage of children presenting with G2Ds was 
higher in our study than in comparable reports.[2,7]
Almost a third of our patients had had an HIV test. Leprosy-HIV 
co-infection was found in 10.0%, and the majority of these had CD4 
counts >200 cells/µL. Case reports have shown that HIV did not 
appear to increase leprosy susceptibility, but co-infected patients 
may have an increased number of reactions.[24] Among our HIV-
positive patients, a few had ENL and none had a type 1 reaction. 
This is in contrast with reports of frequent reactions in co-infected 
patients;  [24,25] however, our numbers were small.
In the present study, 65.0% of patients completed treatment. Half 
of these were cured, and in the remainder cure was not documented. 
Our cure rate was 32.5%, which is lower than the clinical cure rate of 
64 - 100% reported in other studies.[7,28] The loss of 32.5% of patients 
soon after treatment completion meant that cured patients in this 
group were not recorded, contributing to our low recorded cure 
rate. Cure rates have been reported to continue to improve up to 
18  months after completion of treatment.[40] In our study, the follow-
up period was 12 months after completion of therapy. Extending 
the follow-up period could therefore have favourably altered our 
cure rate. Our relapse rate was 3.8%, and all these patients had MB 
leprosy. Reported relapse rates range from 0% to 20%.[29-32] Dacso et 
al.[29] and Ali et al.[30] showed lower relapse rates of 0.8% and 0.84%, 
respectively, in MB patients. Our relapse rates are comparable to rates 
reported in the literature.
The present study highlighted the presence of active areas of leprosy 
transmission, mainly from unknown and possible undiagnosed 
contacts. These mainly result in high bacillary MB forms associated 
with continued infection spread. In addition, imported infections 
were found. Delayed diagnosis is also a focus, as a significant 
number of patients presented with G2Ds. Poor access to specialist 
dermatology services is a reality in parts of our country, which may 
be responsible for the delay in diagnosis.
Active patient detection strategies need to be intensified to facilitate 
early diagnosis and prompt treatment, particularly in KZN. Leprosy 
screening programmes for immigrants, especially from endemic 
areas, at country entry ports should also be considered.
Study limitations
In terms of limitations of the present study, bias in reporting could 
not be excluded, as this was a retrospective analysis. Selection bias is 
also possible, as it was a single-centre study conducted in a tertiary 
hospital. Our sample size was small, and the follow-up period was 
limited to 1 year after treatment completion.
Conclusions
Our analysis of available records shows that despite decreasing 
numbers of leprosy patients in our centre, there are still clusters 
of transmission where MB forms predominate. Furthermore, the 
high rate of G2Ds in new patients, including children, indicates late 
presentation, which is an obstacle to reducing the disease burden 
further. The constant emergence of leprosy infections highlights 
shortfalls in our efforts to achieve the leprosy-free region that was 
envisioned by the WHO for 2020. Our low cure rates and significant 
loss of patients to follow-up pose difficulties in achieving a leprosy-
free region. The need for further efforts aimed at improving early 
diagnosis and community awareness education campaigns cannot be 
over-emphasised.
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